This webinar provides a comprehensive overview of the listing regimes for biotech companies, specialist technology companies, and issuers with weighted voting rights (WVR) structures on the Hong Kong Stock Exchange (HKEX), including the key Listing Rule amendments that took effect on 24 July 2026 following the conclusion of the Exchange's Listing Framework Competitiveness Review.
The presentation covers, among other things:
- The background to HKEX's specialist listing regimes and their role in attracting China's fastest-growing biotech and technology companies
- Chapter 18A requirements for biotech companies, including core product definition, recognised competent authorities (FDA, EMA, NMPA), and clinical trial/regulatory milestones
- Market capitalisation, working capital, sophisticated investor validation, and public float requirements for biotech applicants
- Chapter 18C requirements for specialist technology companies, including commercial vs. pre-commercial classification and R&D expenditure thresholds
- Sophisticated independent investor (SII) and Pathfinder SII requirements, plus post-IPO lock-up periods
- Chapter 8A weighted voting rights eligibility, corporate governance safeguards, and rules for Greater China and grandfathered issuers
- The 24 July 2026 reforms: reduced WVR market cap thresholds, the new 20:1 voting ratio cap, and the New Business Model innovative company test
- Reduced secondary listing thresholds and new flexibility for commercially active biotech and specialist tech companies